Zepbound for Sleep Apnea: What the Evidence Shows (and How It Compares to Wegovy and Other GLP-1s)

For decades, if you had obstructive sleep apnea, the treatment conversation started and ended with a machine. CPAP, the mask-and-hose device that keeps your airway open with a stream of pressurized air, was the gold standard, and for many people it still is. But there was never a pill or an injection you could take for the underlying condition. That changed at the end of 2024, and it's why "Zepbound for sleep apnea" has become one of the most searched health questions of the year.

In December 2024, the FDA approved Zepbound (the brand name for tirzepatide) as the first and only prescription medication for moderate-to-severe obstructive sleep apnea in adults with obesity ^{[1, 2]}. That's a genuine milestone: the first time a drug has been approved to treat sleep apnea itself, not just the daytime sleepiness that comes with it. Naturally, it's raised a flurry of questions. Does it work? How well? Is it better than CPAP? What about Wegovy and Ozempic, do those help too? Let's walk through what the evidence actually shows, without the hype.

What Zepbound is, and how it treats sleep apnea

Zepbound is tirzepatide, the same molecule sold under the name Mounjaro for type 2 diabetes. It belongs to a class of drugs that have transformed obesity treatment. Technically, it's a dual GIP and GLP-1 receptor agonist, meaning it mimics two gut hormones that regulate appetite, blood sugar, and how full you feel. The practical result is significant, sustained weight loss, on the order of 18 to 20 percent of body weight in trials ^[3].

That weight-loss mechanism is the key to understanding how it treats sleep apnea, because the connection is largely, though perhaps not entirely, through the weight. Excess weight, especially fat around the neck, throat, and abdomen, is the single biggest driver of obstructive sleep apnea; it narrows and destabilizes the airway so it's more likely to collapse during sleep. Lose a substantial amount of that weight and the airway becomes less prone to collapsing. So Zepbound doesn't act directly on the airway the way CPAP does. It treats the condition upstream, by reducing the excess weight that's causing it in the first place. Researchers are still investigating whether some of the benefit comes from effects beyond weight loss, such as reduced fluid retention or inflammation, but the weight reduction is clearly the main engine.

What the trial actually found

The approval rested on a pair of studies published together in the New England Journal of Medicine, known as SURMOUNT-OSA ^[4]. The design was clean and worth understanding, because the specifics matter.

The trials enrolled 469 adults with moderate-to-severe obstructive sleep apnea (an apnea-hypopnea index, or AHI, of at least 15 events per hour) and obesity (a BMI of 30 or higher). They were split into two groups: one made up of people who weren't using CPAP, and one of people who were and planned to stay on it. Within each group, participants got either tirzepatide (at the maximum tolerated dose, 10 or 15 mg weekly) or a placebo, for a full year ^{[1, 4]}.

The results were striking. Among participants not using CPAP, Zepbound reduced apnea events by an average of about 25 per hour, compared with just 5 in the placebo group. Among those also using CPAP, it reduced events by about 29 per hour, versus 6 on placebo ^{[2, 5]}. To put that in perspective, the drug reduced sleep apnea severity by roughly 60 percent relative to placebo ^[6]. And after one year, depending on the group, somewhere between 42 and 50 percent of people taking Zepbound had improved so much that they met the criteria for remission or had only mild, non-symptomatic sleep apnea remaining, compared with 14 to 16 percent on placebo ^[5]. Nearly half the patients, in other words, saw their sleep apnea effectively resolve or become clinically insignificant.

Beyond the breathing numbers, participants also lost substantial weight and saw improvements in blood pressure, inflammatory markers, and self-reported sleep quality ^[3]. For a single intervention, that's a lot of connected benefits moving in the right direction at once, which is exactly what you'd expect from something that treats the shared upstream cause.

How it compares to Wegovy, Ozempic, and other GLP-1s

This is where the search traffic gets confused, so let's be precise, because the distinctions matter clinically and legally.

Zepbound and Mounjaro are both tirzepatide. Zepbound is the version branded for weight management and now sleep apnea; Mounjaro is the version branded for type 2 diabetes. Same drug.

Wegovy and Ozempic are both semaglutide, a related but different drug. Semaglutide is a GLP-1 receptor agonist (it hits one of the two receptors tirzepatide does, not both). Wegovy is approved for chronic weight management; Ozempic is approved for type 2 diabetes.

Here's the crucial point for anyone searching this: only Zepbound (tirzepatide) is FDA-approved specifically for obstructive sleep apnea. Wegovy, Ozempic, and the other GLP-1 drugs are not approved for OSA ^[7]. That doesn't mean they don't help. Because the benefit for sleep apnea comes mainly through weight loss, and semaglutide also produces meaningful weight loss, people taking Wegovy or Ozempic for other reasons often see their sleep apnea improve too. Studies and real-world data suggest semaglutide reduces OSA risk and severity, just without a formal OSA indication ^{[8, 9]}.

The practical differences come down to two things. First, the labeled indication: if you want a medication prescribed specifically for sleep apnea, tirzepatide is the one with the approval behind it. Second, the magnitude: in head-to-head weight-loss terms, tirzepatide tends to produce somewhat greater weight loss than semaglutide (roughly 17 percent versus 12 percent in comparative analyses), and since the OSA benefit tracks with weight loss, the drug that drives more weight loss would be expected to do somewhat more for apnea ^[10]. That said, an observational comparison found the difference between the two in reducing OSA risk was not statistically significant, so semaglutide is far from a weak option ^[9]. Other GLP-1 drugs like liraglutide produce less weight loss and correspondingly smaller effects.

The bottom line on the comparison: tirzepatide has the strongest evidence and the only OSA approval, but the whole class helps, largely in proportion to how much weight each drug takes off.

The important caveats

This is genuinely exciting, but responsible coverage has to be clear about the limits, and there are several that matter.

It's approved for people with obesity, not everyone with sleep apnea. The approval and the trial were specifically for adults with a BMI of 30 or higher. Plenty of people have sleep apnea driven by factors other than weight, craniofacial structure, for instance, and for them a weight-loss drug may do little. This is not a universal sleep apnea treatment.

It doesn't replace CPAP for everyone, and the guidelines still consider CPAP first-line. Nearly half of trial participants had their apnea resolve or become mild, but that means more than half still had residual sleep apnea that needed managing. Some people reach a normal AHI on tirzepatide and can, under medical supervision, come off CPAP; others retain meaningful apnea and stay on combination therapy. The only way to know which applies to you is a repeat sleep study after weight loss. Nobody should stop CPAP on their own because they've started a GLP-1.

It has real side effects and requirements. The GLP-1 class commonly causes gastrointestinal side effects, nausea, diarrhea, vomiting, constipation, especially as the dose increases. It carries a boxed warning regarding a risk of thyroid C-cell tumors seen in animal studies, and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome ^[2]. It's a weekly injection, generally taken indefinitely, and the benefits, including for weight and apnea, tend to reverse if the drug is stopped. It's also expensive and not always covered by insurance.

A diagnosis comes first. You can't and shouldn't treat sleep apnea you haven't confirmed. A proper diagnosis, typically via a home sleep test or in-lab study, is the necessary first step, both to establish that you have OSA and to measure your baseline severity so any improvement can be tracked.

Where this fits in a modern approach to sleep apnea

Step back, and the significance of Zepbound isn't that it dethrones CPAP. It's that it validates something sleep and metabolic medicine has been moving toward for years: treating sleep apnea and the excess weight driving it as connected problems, rather than in separate silos.

For a large share of patients, obstructive sleep apnea is downstream of metabolic health. The most effective long-term approach for those patients often isn't choosing between treating the airway and treating the weight; it's doing both in a coordinated way, using CPAP or an oral appliance to manage the breathing now while addressing the underlying weight and metabolic drivers for durable improvement. Medications like tirzepatide have made the "addressing the weight" half of that far more powerful than it used to be. The arrival of an approved drug is best understood as a powerful new tool within that integrated, longitudinal model, not a magic bullet that makes everything else obsolete.

The bottom line

Zepbound (tirzepatide) is a real breakthrough: the first medication ever FDA-approved for obstructive sleep apnea, and in trials it cut apnea severity by roughly 60 percent and brought nearly half of patients to remission or mild disease, while also driving major weight loss and better blood pressure. It works primarily by treating the excess weight that drives sleep apnea, which is why related drugs like Wegovy and Ozempic (semaglutide) also help even without a formal OSA approval, roughly in proportion to the weight they take off. But it's approved specifically for people with obesity, it doesn't replace CPAP for everyone, it carries real side effects, and it requires a proper diagnosis first. Understood correctly, it's not a replacement for everything that came before. It's a powerful new addition to a smarter, more connected way of treating sleep and metabolic health together.

Frequently asked questions

This article is for general education and isn't a substitute for individual medical advice. Zepbound is a prescription medication with important risks and requirements; decisions about it, about CPAP, or about any sleep apnea treatment should be made with your own clinician.